Kumar et al., 2021 - Google Patents

CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells

Kumar et al., 2021

View HTML
Document ID
3661178228987362845
Author
Kumar S
Zeng Z
Bagati A
Tay R
Sanz L
Hartono S
Ito Y
Abderazzaq F
Hatchi E
Jiang P
Cartwright A
Olawoyin O
Mathewson N
Pyrdol J
Li M
Doench J
Booker M
Tolstorukov M
Elledge S
Chédin F
Liu X
Wucherpfennig K
Publication year
Publication venue
Cancer discovery

External Links

Snippet

A number of cancer drugs activate innate immune pathways in tumor cells but unfortunately also compromise antitumor immune function. We discovered that inhibition of CARM1, an epigenetic enzyme and cotranscriptional activator, elicited beneficial antitumor activity in …
Continue reading at aacrjournals.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Similar Documents

Publication Publication Date Title
Kumar et al. CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells
Jackson et al. Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma
Gulla et al. Bortezomib induces anti–multiple myeloma immune response mediated by cGAS/STING pathway activation
Mahadevan et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity
Nath et al. Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment
Zeng et al. Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Demel et al. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer
Leruste et al. Clonally expanded T cells reveal immunogenicity of rhabdoid tumors
Gstalder et al. Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade
Zhu et al. Evasion of innate immunity contributes to small cell lung cancer progression and metastasis
Anandagoda et al. microRNA-142–mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance
Schaafsma et al. VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance
Sato et al. CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade
EP3374497B1 (en) Modified macrophages for use in the treatment of cancer
Jung et al. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell–Intrinsic Dysfunction
Zhang et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
Li et al. Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1
Ajina et al. Antitumor T-cell immunity contributes to pancreatic cancer immune resistance
Suzuki et al. β-catenin drives butyrophilin-like molecule loss and γδ T-cell exclusion in colon cancer
Ito et al. Addressing tumor heterogeneity by sensitizing resistant cancer cells to T cell–secreted cytokines
Welters et al. Immune phenotypes and target antigens of clonally expanded bone marrow T cells in treatment-naïve multiple myeloma
Markovits et al. MYC induces immunotherapy and IFNγ resistance through downregulation of JAK2
Sun et al. Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer
Liang et al. SIX4 controls Anti-PD-1 efficacy by regulating STING expression
Fusagawa et al. Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer